百济神州(06160.HK) 香港及台湾总经理陈益雅指,目前集团在港引入的三款创新药,包括IL-6抑制剧、BTK抑制剂及PD-1抑制剂,其中两款已获得政府资助,可于公立医院使用。集团计划2030年前于港引入4只新药,另料今年下半年在香港会新增两个新适应症。集团于今年首季首次录得盈利,陈益雅指,集团目前的研发费用占销售比例很高,全球研发团队有约1,100人。对比起其他公司会将试验阶段外判,集团会进行...
Source Link百济神州(06160.HK) 香港及台湾总经理陈益雅指,目前集团在港引入的三款创新药,包括IL-6抑制剧、BTK抑制剂及PD-1抑制剂,其中两款已获得政府资助,可于公立医院使用。集团计划2030年前于港引入4只新药,另料今年下半年在香港会新增两个新适应症。集团于今年首季首次录得盈利,陈益雅指,集团目前的研发费用占销售比例很高,全球研发团队有约1,100人。对比起其他公司会将试验阶段外判,集团会进行...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.